Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology.

Abstract

BACKGROUND:

In order to influence every day clinical practice professional organisations issue management guidelines. Cross-sectional surveys are used to evaluate the implementation of such guidelines. The present survey investigated screening for glucose perturbations in people with coronary artery disease and compared patients with known and newly detected type 2 diabetes with those without diabetes in terms of their life-style and pharmacological risk factor management in relation to contemporary European guidelines.

METHODS:

A total of 6187 patients (18-80 years) with coronary artery disease and known glycaemic status based on a self reported history of diabetes (previously known diabetes) or the results of an oral glucose tolerance test and HbA1c (no diabetes or newly diagnosed diabetes) were investigated in EUROASPIRE IV including patients in 24 European countries 2012-2013. The patients were interviewed and investigated in order to enable a comparison between their actual risk factor control with that recommended in current European management guidelines and the outcome in previously conducted surveys.

RESULTS:

A total of 2846 (46%) patients had no diabetes, 1158 (19%) newly diagnosed diabetes and 2183 (35%) previously known diabetes. The combined use of all four cardioprotective drugs in these groups was 53, 55 and 60%, respectively. A blood pressure target of <140/90 mmHg was achieved in 68, 61, 54% and a LDL-cholesterol target of <1.8 mmol/L in 16, 18 and 28%. Patients with newly diagnosed and previously known diabetes reached an HbA1c <7.0% (53 mmol/mol) in 95 and 53% and 11% of those with previously known diabetes had an HbA1c >9.0% (>75 mmol/mol). Of the patients with diabetes 69% reported on low physical activity. The proportion of patients participating in cardiac rehabilitation programmes was low (≈40 %) and only 27% of those with diabetes had attended diabetes schools. Compared with data from previous surveys the use of cardioprotective drugs had increased and more patients were achieving the risk factor treatment targets.

CONCLUSIONS:

Despite advances in patient management there is further potential to improve both the detection and management of patients with diabetes and coronary artery disease.

• Authors: Viveca Gyberg, Dirk De Bacquer, Guy De Backer, Catriona Jennings, Kornelia Kotseva, Linda Mellbin, Oliver Schnell, Jaakko Tuomilehto, David Wood, Lars Rydén, Philippe Amouyel, Jan Bruthans, Almudena Castro Conde, Renata Cifkova, Jaap W Deckers, Johan De Sutter, Mirza Dilic, Maryna Dolzhenko, Andrejs Erglis, Zlatko Fras, Dan Gaita, Nina Gotcheva, John Goudevenos, Peter Heuschmann, Aleksandras Laucevicius, Seppo Lehto, Dragan Lovic, Davor Miličić, David Moore, Evagoras Nicolaides, Raphael Oganov, Andrzej Pająk, Nana Pogosova, Zeljko Reiner, Martin Stagmo, Stefan Störk, Lale Tokgözoğlu, Dusko Vulic, EUROASPIRE Investigators
• Journal: Cardiovascular diabetology (Cardiovasc Diabetol) Vol. 14 Pg. 133 (Oct 01 2015) ISSN: 1475-2840 [Electronic] England
• PMID: 26427624 (Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't)

Chemical References

• Adrenergic beta-Antagonists
• Angiotensin Receptor Antagonists
• Angiotensin-Converting Enzyme Inhibitors
• Antihypertensive Agents
• Cardiotonic Agents
• Cholesterol, LDL
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Hypoglycemic Agents
• Platelet Aggregation Inhibitors

Topics

• Adrenergic beta-Antagonists (therapeutic use)
• Aged
• Angiotensin Receptor Antagonists (therapeutic use)
• Angiotensin-Converting Enzyme Inhibitors (therapeutic use)
• Antihypertensive Agents (therapeutic use)
• Blood Pressure
• Cardiotonic Agents (therapeutic use)
• Cholesterol, LDL (metabolism)
• Coronary Artery Disease (complications, drug therapy)
• Cross-Sectional Studies
• Diabetes Mellitus, Type 2 (complications, drug therapy)
• Dyslipidemias (complications, drug therapy, metabolism)
• Europe
• Female
• Guideline Adherence
• Humans
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Hypertension (complications, drug therapy)
• Hypoglycemic Agents (therapeutic use)
• Male
• Middle Aged
• Platelet Aggregation Inhibitors (therapeutic use)
• Practice Guidelines as Topic
• Registries
• Risk Factors
• Secondary Prevention